NASDAQ : KLRS

Kalaris Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 48.32M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Details

NameKalaris Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees20
Founded2019
CeoAndrew Oxtoby
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS4829291065
Cusip482929106
Cik0001754068
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Andrew OxtobyPresident, Chief Executive Officer and Director
Dr. Srinivas Akkaraju M.D., Ph.D.Director and Co-Founder
Dr. Michael Philip Dybbs Ph.D.Co-Founder and Director
Dr. Napoleone Ferrara M.D.Independent Director and Co-Founder
Dr. Matthew Feinsod M.D.Chief Medical Officer
Liisa Ann Bayko M.B.A.Chief Financial Officer and Treasurer
Amy VandekopInterim Principal Accounting Officer and Corporate Controller
Kristine CurtissSenior Vice President of Clinical
Dr. Jill E. Porter Ph.D.Senior Vice President of CMC

Contact

Address400 Connell Drive, Suite 5500, Berkeley Heights, New Jersey 07922, United States
Phone650 249 2727
Websitehttps://kalaristx.com